LIN7B

Across TCGA pan-cancer cohorts, LIN7B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LIN7B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LIN7B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LIN7B expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where LIN7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.712	0.136	.006	32	view →
GBM	OS	Tertile	All	0.196	0.571	.010	11	view →
HNSC	OS	Tertile	II,III,IV	0.412	0.905	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LIN7B–PDAC (OS)

Open the PDAC breakdown →